OVERALL AND EVENT -FREE SURVIVAL ARE NOT IMPROVED BY THE USE OF MYELO -ABLATIVE THERAPY FOLLOWING INTENSIFIED CHEMOTHERAPY IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA PATIENTS: A PROSPECTIVE RANDOMIZED PHASE III STUDY Running head: High -dose therapy in multiple myeloma